IKKa and IKKb can cooperatively activate NF‐κB and EGFR/AP1 networks of signaling pathways and contribute to the malignant phenotype and the intrinsic or acquired therapeutic resistance of HNSCC 45. This evidence concerns the gene JUN and head and neck squamous cell carcinoma.